JP2022535452A - 抗原結合タンパク質構築物およびその使用 - Google Patents

抗原結合タンパク質構築物およびその使用 Download PDF

Info

Publication number
JP2022535452A
JP2022535452A JP2021572559A JP2021572559A JP2022535452A JP 2022535452 A JP2022535452 A JP 2022535452A JP 2021572559 A JP2021572559 A JP 2021572559A JP 2021572559 A JP2021572559 A JP 2021572559A JP 2022535452 A JP2022535452 A JP 2022535452A
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable domain
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021572559A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535452A5 (enExample
Inventor
アレキサンダー ジェイ． ニコルズ
ブライアン ピー． フィスケ
ニミシュ ゲラ
Original Assignee
ミシック セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミシック セラピューティクス インコーポレイテッド filed Critical ミシック セラピューティクス インコーポレイテッド
Publication of JP2022535452A publication Critical patent/JP2022535452A/ja
Publication of JP2022535452A5 publication Critical patent/JP2022535452A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021572559A 2019-06-07 2020-06-05 抗原結合タンパク質構築物およびその使用 Ceased JP2022535452A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962858932P 2019-06-07 2019-06-07
US62/858,932 2019-06-07
US201962888384P 2019-08-16 2019-08-16
US62/888,384 2019-08-16
PCT/US2020/036495 WO2020247873A1 (en) 2019-06-07 2020-06-05 Antigen-binding protein constructs and uses thereof

Publications (2)

Publication Number Publication Date
JP2022535452A true JP2022535452A (ja) 2022-08-08
JP2022535452A5 JP2022535452A5 (enExample) 2023-06-13

Family

ID=71899864

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021572559A Ceased JP2022535452A (ja) 2019-06-07 2020-06-05 抗原結合タンパク質構築物およびその使用

Country Status (9)

Country Link
US (1) US20220313845A1 (enExample)
EP (1) EP3980129A1 (enExample)
JP (1) JP2022535452A (enExample)
CN (1) CN114746115A (enExample)
AU (1) AU2020289477A1 (enExample)
CA (1) CA3142884A1 (enExample)
IL (1) IL288685A (enExample)
MX (1) MX2021015095A (enExample)
WO (1) WO2020247873A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
JP2025525496A (ja) * 2022-07-08 2025-08-05 イマジナブ・インコーポレーテッド Ｄｌｌ３抗原結合構築物
CN119486763A (zh) * 2022-07-14 2025-02-18 苏州宜联生物医药有限公司 抗体药物偶联物及其制备方法和用途
CN121293357A (zh) 2022-08-22 2026-01-09 雅博得乐医疗公司 Dll3结合分子及其用途
TW202602935A (zh) * 2024-04-01 2026-01-16 美商米西克治療公司 抗原結合蛋白構築體及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521772A (ja) * 2010-03-11 2013-06-13 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
JP2013528354A (ja) * 2010-03-30 2013-07-11 中外製薬株式会社 抗原の消失を促進する、ＦｃＲｎに対するアフィニティーが変更された抗体
JP2018529656A (ja) * 2015-08-20 2018-10-11 アッヴィ・ステムセントルクス・エル・エル・シー 抗ｄｌｌ３抗体薬物コンジュゲートおよび使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
TW201920257A (zh) * 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
MX2012002651A (es) 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
AR078651A1 (es) 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
CN104520324A (zh) * 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521772A (ja) * 2010-03-11 2013-06-13 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
JP2013528354A (ja) * 2010-03-30 2013-07-11 中外製薬株式会社 抗原の消失を促進する、ＦｃＲｎに対するアフィニティーが変更された抗体
JP2018529656A (ja) * 2015-08-20 2018-10-11 アッヴィ・ステムセントルクス・エル・エル・シー 抗ｄｌｌ３抗体薬物コンジュゲートおよび使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate", DRUG IN R&D, vol. 18, no. 4, JPN6024033577, 2018, pages 255 - 258, ISSN: 0005606384 *

Also Published As

Publication number Publication date
AU2020289477A1 (en) 2022-02-03
CN114746115A (zh) 2022-07-12
IL288685A (en) 2022-02-01
EP3980129A1 (en) 2022-04-13
WO2020247873A1 (en) 2020-12-10
CA3142884A1 (en) 2020-12-10
MX2021015095A (es) 2022-03-22
US20220313845A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
JP7635201B2 (ja) 抗原結合タンパク質構築物及びその使用
US12331125B2 (en) Anti-cMet antibody-drug conjugates and uses thereof
US20220313845A1 (en) Antigen-binding protein constructs and uses thereof
KR20250083225A (ko) Lrrc15-결합 단백질 작제물 및 이의 용도
US20240158493A1 (en) Antigen-binding protein constructs and antibodies and uses thereof
CN119421894A (zh) 具有ph依赖性结合的ptk7结合蛋白及其用途
CN114786732A (zh) 抗原结合蛋白构建体及其用途
US20220306751A1 (en) Antigen-binding protein constructs and uses thereof
US20220348679A1 (en) Antigen-binding protein constructs and uses thereof
KR20260007365A (ko) Trop2-결합 단백질 및 이의 용도
HK40114906A (en) Anti-met antibodies and uses thereof
HK40102142B (en) Anti-met antibodies and uses thereof
HK40102142A (en) Anti-met antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211222

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220418

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230605

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250929

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260129

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20260521